Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders

被引：15
|
作者：
Yoon, David S. [1 ]
Wu, Shung C. [1 ]
Seethala, Ramakrishna [2 ]
Golla, Rajasree [2 ]
Nayeem, Akbar [3 ]
Everlof, John G. [4 ]
Gordon, David A. [5 ]
Hamann, Lawrence G. [1 ]
Robl, Jeffrey A. [1 ]
机构：
[1] Bristol Myers Squibb Co, Res & Dev, Dept Chem, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Res & Dev, Lead Evaluat, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Res & Dev, CADD, Princeton, NJ 08543 USA
[4] Bristol Myers Squibb Co, Res & Dev, PCO Discovery Pharmaceut, Princeton, NJ 08543 USA
[5] Bristol Myers Squibb Co, Res & Dev, Dept Biol, Princeton, NJ 08543 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 21期
关键词：
11-Beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1); Enzyme inhibitor; Pyridyl sulfonamide; Type-2; diabetes; SELECTIVE INHIBITORS; VISCERAL OBESITY; POTENT; HYPERGLYCEMIA; DESIGN; MODEL; MICE;
D O I：
10.1016/j.bmcl.2014.09.012
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A previous disclosure from this lab highlighted the discovery of pyridyl amides as potent 11 beta-HSD1 inhibitors. In order to build additional novelty and polarity into this chemotype, replacement of the hydrogen-bonding carbonyl (CO) pharmacophore with the bioisosteric sulfonyl (SO2) group was examined. Despite initial comparisons suggesting the corresponding sulfonamides exhibited weaker activity versus their carbonyl counterparts, further optimization was performed in an effort to identify various potent and unique leads for the program. Judicious incorporation of polar moieties resulted in the identification of compounds with enhanced potency and lipophilicity profiles, resulting in leads with superior aqueous solubility and liver microsomal stability. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5045 / 5049
页数：5
相关论文
共 50 条
  • [41] 11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents
    Boyle, Craig D.
    Kowalski, Timothy J.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (06) : 801 - 825
  • [42] Discovery of novel 7-membered cyclic amide derivatives that inhibit 11beta-hydroxysteroid dehydrogenase type 1
    Udagawa, Shuji
    Sakami, Satoshi
    Takemura, Takahiro
    Sato, Mikiya
    Arai, Takahiro
    Nitta, Aiko
    Aoki, Takumi
    Kawai, Koji
    Iwamura, Tomokatsu
    Okazaki, Seiji
    Takahashi, Takehiro
    Kaino, Mie
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (06) : 1617 - 1621
  • [43] Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors
    McMinn, Dustin L.
    Rew, Yosup
    Sudom, Athena
    Caille, Seb
    DeGraffenreid, Michael
    He, Xiao
    Hungate, Randall
    Jiang, Ben
    Jaen, Juan
    Julian, Lisa D.
    Kaizerman, Jacob
    Novak, Perry
    Sun, Daqing
    Tu, Hua
    Ursu, Stefania
    Walker, Nigel P. C.
    Yan, Xuelei
    Ye, Qiuping
    Wang, Zhulun
    Powers, Jay P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (05) : 1446 - 1450
  • [44] 11β-hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents
    Webster, Scott Peter
    Pallin, Thomas David
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (12) : 1407 - 1422
  • [45] Discovery of Novel 11β-HSD1 Inhibitors by Pharmacophore-Based Virtual Screening
    Kim, Nam Doo
    Lee, Younho
    Han, Chang-Kyun
    Ahn, Soon Kil
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2012, 33 (07) : 2365 - 2368
  • [46] Discovery of novel dual functional agent as PPARγ agonist and 11β-HSD1 inhibitor for the treatment of diabetes
    Ye, Yang-liang
    Zhou, Zhou
    Zou, Han-jun
    Shen, Yu
    Xu, Ti-fei
    Tang, Jing
    Yin, Hua-zhong
    Chen, Min-li
    Leng, Ying
    Shen, Jian-hua
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (15) : 5722 - 5732
  • [47] Spirocyclic ureas: Orally bioavailable 11β-HSD1 inhibitors identified by computer-aided drug design
    Tice, Colin M.
    Zhao, Wei
    Xu, Zhenrong
    Cacatian, Salvacion T.
    Simpson, Robert D.
    Ye, Yuan-Jie
    Singh, Suresh B.
    McKeever, Brian M.
    Lindblom, Peter
    Guo, Joan
    Krosky, Paula M.
    Kruk, Barbara A.
    Berbaum, Jennifer
    Harrison, Richard K.
    Johnson, Judith J.
    Bukhtiyarov, Yuri
    Panemangalore, Reshma
    Scott, Boyd B.
    Zhao, Yi
    Bruno, Joseph G.
    Zhuang, Linghang
    McGeehan, Gerard M.
    He, Wei
    Claremon, David A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (03) : 881 - 886
  • [48] Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis?
    Harno, Erika
    White, Anne
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2010, 21 (10) : 619 - 627
  • [49] Adamantyl Ethanone Pyridyl Derivatives: Potent and Selective Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1
    Su, Xiangdong
    Pradaux-Caggiano, Fabienne
    Vicker, Nigel
    Thomas, Mark P.
    Halem, Heather
    Culler, Michael D.
    Potter, Barry V. L.
    CHEMMEDCHEM, 2011, 6 (09) : 1616 - 1629
  • [50] Identification of Cyclicsulfonamide Derivatives with an Acetamide Group as 11β-Hydroxysteroid Dehydrogenase 1 Inhibitors
    Kim, Se Hoan
    Kwon, Sung Wook
    Chu, So Young
    Lee, Jae Hong
    Narsaiah, Banda
    Kim, Chi Hyun
    Kang, Seung Kyu
    Kang, Nam Sook
    Dal Rhee, Sang
    Bae, Myung Ae
    Ahn, Sung Hoon
    Ha, Duck Chan
    Kim, Ki Young
    Ahn, Jin Hee
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2011, 59 (01) : 46 - 52
12345